glp-1 obesity drugs pipeline In 5 years, went from 15% weight loss (Wegovy) to 29% (Retatrutide). But efficacy is only half the story. Look at the pipeline: 50+ drugs across 8+ distinct mechanisms. GLP-1s glp-1 pipeline The GLP-1 race

PMID 29236221

The development of rare adverse events, which may not occur until a patient has been on a drug for a number of years, is of concern, but until more patients are followed for an adequate period of time, the true safety of a drug cannot be stated or concluded

Weight loss is not a side effect but the primary endpoint

GLP-1 receptor agonists reduce body weight by decreasing food intake, improving insulin sensitivity as well as delaying gastric emptying

In addition, in a rat model of IBS, intraperitoneal administration of exendin-4 normalized stress-induced defecation and visceral pain sensitivity, without affecting centrally regulated anxiety-like behaviors [56]